Trial Profile
A Retrospective Chart Review Study Assessing Dosing Patterns and Outcomes of Ceritinib In Patients With ALK-Positive Non-Small Cell Lung Cancer In A Real-World Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Apr 2017
Price :
$35
*
At a glance
- Drugs Ceritinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Apr 2017 Results published in the Advances in Therapy
- 19 Dec 2016 New trial record
- 01 Nov 2016 Results published in the Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.